Diving Deep Into the CEPHEUS Trial: Subcutaneous Dara-VRd vs VRd in Transplant-Ineligible or Transplant-Deferred NDMM

The FDA granted orphan drug designation to OPN-6602 for the potential treatment of relapsed/refractory multiple myeloma.

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

Binod Dhakal, MD, MS, discussed the use of bispecific antibodies and chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma treatment.

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

One concern with bispecific antibody therapies in community settings is managing adverse events, with emerging patterns guiding management strategies.

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to CAR T-cell therapy in multiple myeloma.